Literature DB >> 18625435

Hepatitis C virus entry and neutralization.

Zania Stamataki1, Joe Grove, Peter Balfe, Jane A McKeating.   

Abstract

The processes of hepatitis C virus (HCV) entry and antibody-mediated neutralization are intimately linked. The high frequency of neutralizing antibodies (nAbs) that inhibit E2-CD81 interaction(s) suggests that this is a major target for the humoral immune response. The observation that HCV can transmit to naive cells by means of CD81-dependent and -independent routes in vitro awaits further investigation to assess the significance in vivo but may offer new strategies for HCV to escape nAbs. The identification of claudins in the entry process highlights the importance of cell polarity in defining routes of HCV entry and release, with recent experiments suggesting a polarized route of viral entry into cells in vitro. In this review, the authors summarize the current understanding of the mechanism(s) defining HCV entry and the role of nAbs in controlling HCV replication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18625435     DOI: 10.1016/j.cld.2008.03.008

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  21 in total

1.  Will there be a vaccine to protect against the hepatitis C virus?

Authors:  Benoît Callendret; Christopher M Walker
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

Review 2.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

3.  Identification of a claudin-4 residue important for mediating the host cell binding and action of Clostridium perfringens enterotoxin.

Authors:  Susan L Robertson; James G Smedley; Bruce A McClane
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

4.  A synthetic peptide corresponding to the extracellular loop 2 region of claudin-4 protects against Clostridium perfringens enterotoxin in vitro and in vivo.

Authors:  Archana Shrestha; Susan L Robertson; Jorge Garcia; Juliann Beingasser; Bruce A McClane; Francisco A Uzal
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

5.  Computational reconstruction of Bole1a, a representative synthetic hepatitis C virus subtype 1a genome.

Authors:  Supriya Munshaw; Justin R Bailey; Lin Liu; William O Osburn; Kelly P Burke; Andrea L Cox; Stuart C Ray
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

6.  Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.

Authors:  Isabel Fofana; Samira Fafi-Kremer; Patric Carolla; Catherine Fauvelle; Muhammad Nauman Zahid; Marine Turek; Laura Heydmann; Karine Cury; Juliette Hayer; Christophe Combet; François-Loïc Cosset; Thomas Pietschmann; Marie-Sophie Hiet; Ralf Bartenschlager; François Habersetzer; Michel Doffoël; Zhen-Yong Keck; Steven K H Foung; Mirjam B Zeisel; Françoise Stoll-Keller; Thomas F Baumert
Journal:  Gastroenterology       Date:  2012-04-10       Impact factor: 22.682

7.  Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection.

Authors:  Lin Liu; Brian E Fisher; Kimberly A Dowd; Jacquie Astemborski; Andrea L Cox; Stuart C Ray
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

8.  Claudin association with CD81 defines hepatitis C virus entry.

Authors:  Helen J Harris; Christopher Davis; Jonathan G L Mullins; Ke Hu; Margaret Goodall; Michelle J Farquhar; Christopher J Mee; Kitty McCaffrey; Stephen Young; Heidi Drummer; Peter Balfe; Jane A McKeating
Journal:  J Biol Chem       Date:  2010-04-07       Impact factor: 5.157

9.  Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells.

Authors:  Christopher J Mee; Helen J Harris; Michelle J Farquhar; Garrick Wilson; Gary Reynolds; Christopher Davis; Sven C D van IJzendoorn; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

Review 10.  Using high-throughput genomics to study hepatitis C: what determines the outcome of infection?

Authors:  Kathie-Anne Walters; Michael G Katze
Journal:  Antiviral Res       Date:  2009-01-07       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.